初级硬化胆管炎中的免疫激活:系统性审查和对炎症性肠道疾病的比较分析
Md Moniruzzaman1,2,3, Ayesha Shah3, Thomas Fairlie1,3
1Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland, Translational Research Institute, Brisbane, Australia.
United European gastroenterology journal
|September 30, 2025
概括
原发性硬化性胆道炎 (PSC) 和炎症性肠病 (IBD) 呈现出不同的免疫特征. PSC涉及增加的Th17细胞和减少的调节性T细胞 (Tregs),使其与IBD区分开来.
科学领域:
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
背景情况:
- 初级硬化胆炎 (PSC) 是一种慢性肝病,其特征是免疫失调和胆道纤维化.
- PSC经常与炎症性肠病 (IBD),特别是性结肠炎同时发生,这表明共享或独特的免疫机制.
研究的目的:
- 系统地审查和比较PSC患者的免疫激活模式与没有PSC的IBD.
- 通过分析免疫差异,更深入地了解PSC的病理生理学.
主要方法:
- 在MEDLINE,Scopus,Cochrane图书馆和Embase数据库中搜索到2024年7月的PSC免疫概况研究.
- 包括报告PSC患者免疫细胞概况,细胞因子水平和基因表达的研究.
- 对比PSC患者 (有或没有IBD) 与仅有IBD患者的免疫特征.
主要成果:
- 分析了23篇文章,涉及638名PSC和557名非PSC/非IBD受试者.
- 与对照人群相比,PSC患者表现出全身,胆道和肝脏免疫激活,特别是结合素β7+肠道T细胞,IL-2和IL-10的增加.
- 与IBD患者相比,PSC患者的系统调节性T细胞 (Tregs) 较少,但PSC肝脏组织显示出更多的Th17细胞,IL-1β和TNF-α,B细胞,IL-2和IL-10比IBD粘膜更少.
结论:
- 独特的免疫激活模式将PSC与没有PSC的IBD患者区分开来.
- Th17细胞的上调和Treg功能的下调是PSC免疫特征的特征.
- 其他免疫参数并不能始终区分PSC和IBD.
相关概念视频
01:17Chronic Bowel Disorders: Introduction
747
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
747
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
903
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
903
01:30Inflammatory Bowel Disease II: Crohn's Disease
960
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
960
01:29Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
643
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
643
01:29Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460